Caliway Biopharmaceuticals Co (ROCO:6919) EV-to-EBIT : -134.62 (As of Jun. 20, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Caliway Biopharmaceuticals Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Caliway Biopharmaceuticals Co's Enterprise Value is NT$65,690.62 Mil. Caliway Biopharmaceuticals Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-487.96 Mil. Therefore, Caliway Biopharmaceuticals Co's EV-to-EBIT for today is -134.62.

The historical rank and industry rank for Caliway Biopharmaceuticals Co's EV-to-EBIT or its related term are showing as below:

ROCO:6919' s EV-to-EBIT Range Over the Past 10 Years
Min: -181.92 Med: -115.89 Max: -22.93
Current: -134.63

During the past 5 years, the highest EV-to-EBIT of Caliway Biopharmaceuticals Co was -22.93. The lowest was -181.92. And the median was -115.89.

ROCO:6919's EV-to-EBIT is ranked worse than
100% of 438 companies
in the Biotechnology industry
Industry Median: 8.67 vs ROCO:6919: -134.63

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Caliway Biopharmaceuticals Co's Enterprise Value for the quarter that ended in Dec. 2023 was NT$23,158.98 Mil. Caliway Biopharmaceuticals Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-487.96 Mil. Caliway Biopharmaceuticals Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -2.11%.

Caliway Biopharmaceuticals Co EV-to-EBIT Historical Data

The historical data trend for Caliway Biopharmaceuticals Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Caliway Biopharmaceuticals Co EV-to-EBIT Chart

Caliway Biopharmaceuticals Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

-22.61

-47.46

Caliway Biopharmaceuticals Co Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial			-	-	-22.61	-	-47.46

Competitive Comparison of Caliway Biopharmaceuticals Co's EV-to-EBIT

For the Biotechnology subindustry, Caliway Biopharmaceuticals Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Caliway Biopharmaceuticals Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Caliway Biopharmaceuticals Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Caliway Biopharmaceuticals Co's EV-to-EBIT falls into.

Caliway Biopharmaceuticals Co EV-to-EBIT Calculation

Caliway Biopharmaceuticals Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	65690.615	/	-487.957
	=	-134.62

Caliway Biopharmaceuticals Co's current Enterprise Value is NT$65,690.62 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Caliway Biopharmaceuticals Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-487.96 Mil.

Caliway Biopharmaceuticals Co (ROCO:6919) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Caliway Biopharmaceuticals Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-487.957	/	23158.981
	=	-2.11 %

Caliway Biopharmaceuticals Co's Enterprise Value for the quarter that ended in Dec. 2023 was NT$23,158.98 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Caliway Biopharmaceuticals Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-487.96 Mil.

Caliway Biopharmaceuticals Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Caliway Biopharmaceuticals Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Caliway Biopharmaceuticals Co (ROCO:6919) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Caliway Biopharmaceuticals Co Ltd (ROCO:6919) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.99, Sec. 1, Xintai 5th Road, 32F.-9, Xizhi District, New Taipei City, TWN, 221

Website

https://www.caliway.com.tw

Caliway Biopharmaceuticals Co Ltd is specialized in the development of new drugs for medical aesthetic and inflammatory diseases. Its leading candidate, CBL-514, is a new drug that can trigger adipocyte apoptosis at the injection site and effectively reduce subcutaneous fat without causing tissue necrosis or prominent side effects.

Caliway Biopharmaceuticals Co (ROCO:6919) Headlines

No Headlines